Early disease identification and intervention are basic tenets in medicine. For psychotic disorders, treatment during the first few years is critical in shaping patients\' long-term outcomes ([@bib6]; [@bib15]). In first-episode psychosis patients, three or more months of remission during the first 2 years is predictive of good functional recovery ([@bib10]). In schizophrenia, relapses are associated with progressively longer times to remission, worse subsequent treatment responses, and psychosocial deterioration ([@bib19]). Antipsychotic maintenance treatment is associated with reduced relapse and better health-related quality of life ([@bib18]).

Schizoaffective disorder patients experience significant symptoms of both psychosis (*e.g*., hallucinations, delusions, disorganized thought) and mood (*e.g*., depression or mania) ([@bib4]). Onset is typically in early adulthood, although the diagnosis may occur years following initial psychiatric symptoms ([@bib9]; [@bib23]). Poor treatment adherence, a well-documented problem in the management of schizoaffective disorder and schizophrenia, is a strong predictor of relapse ([@bib3]; [@bib7]; [@bib15]; [@bib20]; [@bib24]). Long-acting injectable antipsychotic therapies provide therapeutic plasma concentrations over weeks to months and eliminate the need for daily oral treatment administration. In real-world settings, long-acting antipsychotic treatment is often reserved for chronically ill patients who are poorly compliant or experience frequent relapses. However, evidence suggests that their early initiation is associated with greater responsiveness, reduced risk for relapse, and improved long-term functioning ([@bib15]; [@bib17]; [@bib21]; [@bib28]). Paliperidone palmitate once-monthly (PP1M) is an efficacious treatment for schizophrenia and schizoaffective disorder (Invega Sustenna Prescribing Information; [@bib16]). This analysis builds on findings from a PP1M schizoaffective disorder study ([@bib13]) by examining effects by duration of illness.

METHODS
=======

Primary Trial Study Design
--------------------------

This analysis examined data from a study of adults with schizoaffective disorder experiencing a recent exacerbation of psychosis with depressive and/or manic mood symptoms ([@bib13]). Study phases included 13-week open-label (OL) acute treatment with PP1M (monotherapy or with prestudy stable doses of mood stabilizers or antidepressants), 12-week OL stabilization with PP1M, and 15-month double-blind (DB) relapse prevention, where subjects were randomized to continue PP1M or withdrawal to placebo (Supplemental Figure 1, <http://links.lww.com/JNMD/A28>). OL stabilization, required to enter the DB phase, was defined as Positive and Negative Syndrome Scale (PANSS) total score of 70 or lower and Young Mania Rating Scale (YMRS) and Hamilton Rating Scale for Depression 21-item (HAM-D-21) scores of 12 or lower.

Analysis Sets and Statistical Evaluations
-----------------------------------------

Subpopulations were defined by time since first psychiatric diagnosis as recent onset (*i.e*., ≤5 years) and chronic illness (*i.e*., \>5 years). The patients\' psychiatric history was obtained from medical records, patient recall, and the study intake interview (including the Structured Clinical Interview for *DSM-IV* diagnosis). Study measures included PANSS, HAM-D-21, YMRS, Clinical Global Impression of Severity for Schizoaffective Disorder (CGI-S-SCA), and Personal and Social Performance Scale (PSP). Mean changes were compared between subpopulations by *t*-tests and within subpopulations by paired *t*-tests. Percentages of subjects meeting OL stabilization criteria were compared using chi-square tests. Treatment differences in relapse were evaluated by a log-rank test. Time to relapse was estimated by the Kaplan-Meier method. Risk-of-relapse estimates (hazard ratio \[HR\] and 95% confidence interval \[CI\]) were determined by Cox proportional hazards models. Patients reported adverse events (AEs) and rated the Medication Satisfaction Questionnaire (MSQ; satisfied \[scores 1--4\] and dissatisfied \[scores 5--7\]). Between treatment differences for proportions were assessed using the Cochran-Mantel-Haenszel chi-Square test with modified ridit scores. No adjustments were made for multiplicity. AE rates were summarized.

RESULTS
=======

OL Acute Treatment and Stabilization Phases
-------------------------------------------

Of 667 subjects enrolled, 206 (30.9%) met the definition for recent onset and 461 (69.1%) for chronic illness (Supplemental Figure 1, <http://links.lww.com/JNMD/A28>). The mean (SD) time since first psychiatric diagnosis was 2.9 (1.4) years in the recent onset group and 18.1 (9.78) years in the chronic illness group (*p \<* 0.001). Subpopulations differed in age, race, body mass index, and some disease characteristics, with no significant differences in symptom or function scores (Table [1](#T1){ref-type="table"}). All subjects received PP1M, with a similar dose distribution at endpoint (2.9% at 78 mg, 7.3% at 117 mg, 50.5% at 156 mg, and 39.3% at 234 mg in recent onset; 2.6%, 7.4%, 53.8%, and 36.2%, respectively, in chronic illness). Both subpopulations had significant improvements in mean psychotic, mood, and function scores at endpoint (all *p \<* 0.001; Fig. [1](#F1){ref-type="fig"}), with greater improvements in the recent onset versus chronic illness subpopulations (all *p ≤* 0.022). A greater percentage of recent onset subjects had a PSP total score higher than 70 (46.6% \[90/143\] *vs*. 29.4% \[126/429\]; *p* = 0.026), and met stabilization criteria (70.4% \[143/203\] *vs*. 60.0% \[270/450\], respectively; *p* = 0.010) at endpoint. Proportions of subjects satisfied (MSQ) with PP1M increased from 32.5% and 40.7% in the recent onset and chronic illness groups at baseline to 74.4% and 75.9%, respectively, at endpoint. Rates of AEs or discontinuations were not higher in the recent onset than the chronic illness subpopulation. Discontinuation rates were 42.2% and 53.4% of subjects, respectively (Table [2](#T2){ref-type="table"}, Supplemental Figure 1, <http://links.lww.com/JNMD/A28>).

###### 

Subject Characteristics at OL Baseline
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![Changes in PANSS, HAM-D-21, YMRS, PSP, and percentage of subjects meeting stabilization criteria with PP1M treatment in the OL acute and stabilization phases. Subjects in both subpopulations exhibited significant improvements from baseline in PANSS total score, HAM-D-21 total score, YMRS total score, and PSP (paired *t*-test). In comparisons between the recent onset and chronic illness patients, significantly greater improvements were observed among the recent onset (*t*-test). A significantly higher percentage of subjects with recent onset illness entered the DB phase (chi-square test). Implications of instrument score changes: PANSS, HAM-D-21, and YMRS---negative changes indicate improvement; PSP---positive change indicates improvement.](nmd-205-324-g002){#F1}
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OL Paliperidone Monthly Treatment Phases: TEAEs and AEs of Interest
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DB Relapse Prevention Phase
---------------------------

In the recent onset subpopulation, time to relapse was longer with PP1M than placebo (log-rank test, *p* = 0.014; Supplemental Figure 2, <http://links.lww.com/JNMD/A29>). Relapse rates were 30.0% (18/60) with placebo and 10.2% (6/59) with PP1M (HR: 2.81; 95% CI: 1.11--7.12; *p* = 0.029). In the chronic illness subpopulation, time to relapse was also longer with PP1M than placebo (log-rank test *p* = 0.001; Supplemental Figure 3, <http://links.lww.com/JNMD/A30>). Relapse rates were 35.5% (39/110) with placebo and 18.1% (19/105) with PP1M (HR: 2.38; 95% CI: 1.37--4.12; *p* = 0.002). Rates of AEs or discontinuations were not higher in the recent onset than the chronic illness subpopulation (Supplemental Table 1, <http://links.lww.com/JNMD/A31>; Supplemental Figure 1, <http://links.lww.com/JNMD/A28>).

DISCUSSION
==========

Findings demonstrated the beneficial effects of PP1M for subjects with a recent onset of psychiatric illness and those with more chronic illness. During the OL acute and stabilization phases, effects were more robust in the recent onset patients. Results in the subsequent relapse prevention phase were similar to those observed in the total study population ([@bib13]); PP1M was associated with significantly lower relapse than placebo was, with numerically lower rates in the recent onset versus the chronic illness subpopulation. Taken together, these results support the potential value of early intervention with PP1M and are consistent with previous reports ([@bib15]; [@bib17]; [@bib21]; [@bib28]) that patients early in their psychiatric illness are often more responsive to treatment. Furthermore, they add to the growing body of evidence on the effects of PP1M in recently diagnosed schizophrenia patients ([@bib8]; [@bib12]; [@bib26]; [@bib27]; [@bib30]), including prospective parallel-group comparisons showing benefits with PP1M compared with daily oral antipsychotic treatment ([@bib1]; [@bib25]). In these patients, the tolerability of PP1M\'s initiation dosing was similar to oral risperidone ([@bib14]). During longer-term exposure, tolerability was similar to risperidone long-acting injection ([@bib12]), with no unexpected findings compared with placebo or no treatment ([@bib8]; [@bib26]). The current analysis did not show recent onset subjects were less tolerant of treatment, as reported by others ([@bib2]; [@bib11]; [@bib22]).

Recent work identifies a potential underlying pathophysiological mechanism that supports these findings. This evidence suggests that brain abnormalities are particularly progressive early in the course of schizophrenia with associated reductions in frontal lobe intracortical myelination ([@bib5]; [@bib29]). Treatment of first-episode patients with long-acting risperidone was associated with a significantly increased intracortical myelination volume compared with daily oral risperidone ([@bib5]). Similar mechanisms may exist in schizoaffective disorder.

The original study was not powered for this subgroup analysis and some baseline differences existed between subpopulations (Table [1](#T1){ref-type="table"}); most were likely driven by the different duration of illness. Also, the survival curves crossed in the recent onset subpopulation (Supplemental Figure 2, <http://links.lww.com/JNMD/A29>). Although this is often found in underpowered studies, a significant effect of PP1M was still observed. Notably, subjects\' age at first schizoaffective disorder diagnosis was approximately 31 years in both subpopulations. This reflects the longitudinal nature of establishing a diagnosis of schizoaffective disorder (*i.e*., the diagnosis is established years after psychiatric illness is first recognized) ([@bib9]; [@bib23]). The mean age at first psychiatric diagnosis was approximately 24 years in the chronic illness and 31 years in the recent onset subjects. This difference may reflect an artifact of taking a database of adults (aged 18--65 years) and then identifying the subgroup of 5 years or less from their first diagnosis. In addition, the lower dropout rate in recent onset patients and the longer period of time in treatment may have contributed to better outcome in this subpopulation. Finally, the differential stabilization rate (eligibility for entry into the DB phase) in the OL phase between the recent onset and chronic illness patients represents an ascertainment bias for the DB phase. This limits the validity of any direct comparisons between the subpopulations in the DB phase.

In conclusion, PP1M significantly improved symptoms and reduced relapse in subjects with schizoaffective disorder. This was evident in both the recent onset and chronic illness subpopulations, with a more pronounced effect in patients earlier in their illness. Assuring antipsychotic intervention in the first years after a diagnosis of psychosis is increasingly accepted as a basic and critical tenet for improving the disease course and outcomes. This is supported by emerging biomarker evidence. Growing evidence may challenge the status quo supporting the use of long-acting antipsychotics earlier in the course of illness.
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